Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McGill

Showing results (11-20 of 277) with videos related to

Pageof 28
Sort By:
Postgraduate Medicine|June 4, 2009
Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studiesJanet B McGill
Postgraduate Medicine|January 31, 2009
Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetesJanet B McGill
Diabetes/Metabolism Research and Reviews|May 4, 2011
Reduction in insulin sensitivity following administration of the clinically used low-dose pressor, norepinephrineNadia Khoury, Janet B McGill
Retina (Philadelphia, Pa.)|August 16, 2024
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHYRithwick Rajagopal, Janet B McGill
The American Journal of Cardiology|November 20, 2019
Safety of Sodium-Glucose Co-Transporter 2 InhibitorsJanet B McGill, Savitha Subramanian
Diabetes Technology & Therapeutics|June 7, 2017
Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome StudiesJanet B McGill, Andrew Ahmann
Clinical Cardiology|February 24, 2001
Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertensionJ B McGill, P A Reilly
Diabetes, Obesity & Metabolism|February 4, 2020
Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney diseaseKatherine R Tuttle, Janet B McGill
Mayo Clinic Proceedings|December 1, 1975
Surreptitious laxative ingestion. Delayed recognition of a serious condition: a case reportN F LaRusso, D B McGill
Advances in Chronic Kidney Disease|October 19, 2006
Epidemiology of obesity and chronic kidney diseaseWill R Ross, Janet B McGill
Pageof 28

Showing results (11-20 of 277) with videos related to

Sort By:
Pageof 28
Postgraduate Medicine|June 4, 2009
Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studiesJanet B McGill
Postgraduate Medicine|January 31, 2009
Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetesJanet B McGill
Diabetes/Metabolism Research and Reviews|May 4, 2011
Reduction in insulin sensitivity following administration of the clinically used low-dose pressor, norepinephrineNadia Khoury, Janet B McGill
Retina (Philadelphia, Pa.)|August 16, 2024
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHYRithwick Rajagopal, Janet B McGill
The American Journal of Cardiology|November 20, 2019
Safety of Sodium-Glucose Co-Transporter 2 InhibitorsJanet B McGill, Savitha Subramanian
Diabetes Technology & Therapeutics|June 7, 2017
Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome StudiesJanet B McGill, Andrew Ahmann
Clinical Cardiology|February 24, 2001
Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertensionJ B McGill, P A Reilly
Diabetes, Obesity & Metabolism|February 4, 2020
Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney diseaseKatherine R Tuttle, Janet B McGill
Mayo Clinic Proceedings|December 1, 1975
Surreptitious laxative ingestion. Delayed recognition of a serious condition: a case reportN F LaRusso, D B McGill
Advances in Chronic Kidney Disease|October 19, 2006
Epidemiology of obesity and chronic kidney diseaseWill R Ross, Janet B McGill
Pageof 28